肾积水治疗市场 - 按类型、适应症、诊断、治疗、年龄层和全球预测，2024 年 - 2032 年

在该领域研发进步的推动下，2024 年至 2032 年间，全球肾积水治疗市场的复合年增长率将达到 8.2%。随着医学科学不断发现新的见解和技术，肾积水的创新治疗方式正在出现。例如，2022 年 9 月，内华达大学里诺分校的研究人员发现了两种促进尿液从肾臟流向输尿管的重要离子通道。他们探索了从肾盂到输尿管的肌肉收缩机制，增强了对尿液运动的理解。合着者 Nathan Grainger 博士强调了这项研究对人类健康的重要性，因为它旨在开发针对肾积水治疗的特定离子通道的疗法。

这些进展为患有这种疾病的患者提供了有希望的解决方案，从而增加了对有效疗法的需求。此外，医疗保健专业人员和患者对早期诊断和治疗重要性的认识不断提高，进一步推动了市场的成长。随着人们越来越重视以患者为中心的照护和改善结果，迫切需要新的治疗方法来解决肾积水的根本原因。因此，该领域不断增加的研究和开发工作有助于满足对先进疗法不断增长的需求。

整个肾积水治疗行业根据类型、适应症、诊断、治疗、年龄层和地区进行分类。

从2024年到2032年，外源性部分将经历严格的发展。当医疗保健专业人员诊断和处理此类外在原因时，同时需要有效的治疗方法来解决由此产生的肾积水。这项需求推动了持续的研究和开发工作，以创新能够减轻症状和保护肾功能的治疗干预措施。因此，肾积水治疗市场的需求不断增加，因为它迎合了导致这种情况的多种原因。

从2024 年到2032 年，双侧肾积水部分的肾积水治疗市场份额将出现显着的复合年增长率。治疗解决方案的需求。由于双侧肾积水可导致肾损伤和肾衰竭等严重併发症，因此对能够缓解症状并改善患者预后的创新治疗方案的需求不断增加。因此，随着医疗保健提供者和患者寻求量身定制的干预措施来解决双侧肾积水的复杂性并减轻其对肾功能的不利影响，肾积水治疗市场的需求正在增加。

2024年至2032年，亚太地区肾积水治疗市场将呈现出值得称讚的复合年增长率。上升。此外，改善医疗基础设施和获得医疗服务的机会使更多的人能够寻求这种疾病的诊断和治疗。该地区人口老化和生活方式的改变进一步推动了对有效肾积水治疗的需求。因此，製造商和医疗保健提供者对专为满足亚太地区患者特定需求而量身定制的创新疗法的需求大幅上升。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 肾臟疾病盛行率上升
    • 尿路感染相关患者人数增加
    • 对微创手术的需求不断增长
    • 越来越多地采用先进的成像技术进行诊断
  • 产业陷阱与挑战
    • 认识不足，治疗费用高
• 成长潜力分析
• 监管环境
• 报销场景
• 技术景观
• 波特的分析
• PESTEL分析
• 流行病学展望
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 单侧肾积水
• 双侧肾积水

第 6 章：市场估计与预测：按指标划分，2018 年 - 2032 年

• 主要趋势
• 固有的
  • 急性单侧阻塞性泌尿道病
  • 肾结石
  • 膀胱癌
  • 膀胱结石
  • 尿道狭窄
  • 骨盆腔器官脱垂
  • 其他内在迹象
• 外在
  • 腹膜后纤维化
  • 卵巢静脉症候群
  • 其他外在迹象

第 7 章：市场估计与预测：按诊断，2018 - 2032

• 主要趋势
• 实验室测试
  • 尿液分析
  • 全血球计数
  • 电解质分析
  • 其他实验室测试
• 影像学
  • 超音波
  • 静脉肾盂造影
  • KUB X 射线
  • CT扫描
  • 其他成像类型

第 8 章：市场估计与预测：按处理方式，2018 - 2032

• 主要趋势
• 震波碎石术
• 腹腔镜检查
• 膀胱导尿术
• 类固醇治疗
• 其他治疗

第 9 章：市场估计与预测：按年龄组别划分，2018 年 - 2032 年

• 主要趋势
• 成人
• 儿科

第 10 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• The Anthem Group
• F. Hoffmann-La Roche Ltd.
• Nephrogenex Inc.
• Novartis AG
• Pfizer Inc.
• Phraxis Inc.
• Renal Associates P.A.
• Sanofi

Global Hydronephrosis Treatment Market will witness 8.2% CAGR between 2024 and 2032, propelled by advancements in research and development within the field. As medical science continues to uncover new insights and technologies, innovative treatment modalities for hydronephrosis are emerging. For instance, in September 2022, researchers at the University of Nevada, Reno, identified two essential ion channels facilitating urine flow from kidneys to ureters. They explored muscle contraction mechanisms from the renal pelvis to the ureters, enhancing comprehension of urine movement. Nathan Grainger, Ph.D., co-author, highlighted the significance of this research for human health, as it aims at developing therapeutics targeting specific ion channels for hydronephrosis treatment.

These developments offer promising solutions for patients suffering from this condition, driving up demand for effective therapies. Moreover, increased awareness among healthcare professionals and patients regarding the importance of early diagnosis and treatment further fuels market growth. With a growing emphasis on patient-centric care and improved outcomes, there's a pressing need for novel treatments that address the underlying causes of hydronephrosis. Consequently, the rising research and development efforts in this field are instrumental in meeting the escalating demand for advanced therapies.

The overall Hydronephrosis Treatment Industry is classified based on the type, indication, diagnosis, treatment, age group, and region.

The extrinsic segment will undergo rigorous development from 2024 to 2032. These conditions, such as tumors, pregnancy, or enlarged organs, can compress the urinary tract, leading to hydronephrosis. As healthcare professionals diagnose and manage such extrinsic causes, there's a concurrent need for effective treatments addressing the resulting hydronephrosis. This demand fuels ongoing research and development efforts to innovate therapeutic interventions capable of alleviating symptoms and preserving renal function. Consequently, the market for hydronephrosis treatments experiences increased demand as it caters to the diverse etiologies contributing to this condition.

The hydronephrosis treatment market share from the bilateral hydronephrosis segment will register a notable CAGR from 2024 to 2032. This condition, characterized by the obstruction of both kidneys, presents unique challenges that drive the need for effective therapeutic solutions. As bilateral hydronephrosis can lead to severe complications such as kidney damage and renal failure, there is a heightened demand for innovative treatment options that can alleviate symptoms and improve patient outcomes. Consequently, the market for hydronephrosis treatments is experiencing increased demand as healthcare providers and patients seek interventions tailored to address the complexities of bilateral hydronephrosis and mitigate its adverse effects on renal function.

Asia Pacific hydronephrosis treatment market will showcase a commendable CAGR from 2024 to 2032. With a growing population and increasing awareness of urological conditions, there is a rising prevalence of hydronephrosis cases in the region. Additionally, improving healthcare infrastructure and access to medical services enable more individuals to seek diagnosis and treatment for this condition. The demand for effective hydronephrosis treatments is further fueled by the region's aging population and changing lifestyle patterns. As a result, manufacturers and healthcare providers are witnessing a significant uptick in demand for innovative therapies tailored to meet the specific needs of patients in the Asia-Pacific region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of kidney diseases
    • 3.2.1.2 Increasing patient population related to urinary tract infections
    • 3.2.1.3 Growing demand for minimally invasive procedures
    • 3.2.1.4 Increasing adoption of advanced imaging techniques for diagnosis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness and high treatment cost
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis
• 3.9 Epidemiology outlook
• 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Unilateral hydronephrosis
• 5.3 Bilateral hydronephrosis

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intrinsic
  • 6.2.1 Acute unilateral obstructive uropathy
  • 6.2.2 Kidney stone
  • 6.2.3 Bladder cancer
  • 6.2.4 Bladder stones
  • 6.2.5 Urethral stricture
  • 6.2.6 Pelvic organ prolapse
  • 6.2.7 Other intrinsic indications
• 6.3 Extrinsic
  • 6.3.1 Retroperitoneal fibrosis
  • 6.3.2 Ovarian vein syndrome
  • 6.3.3 Other extrinsic indications

Chapter 7 Market Estimates and Forecast, By Diagnosis, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Laboratory tests
  • 7.2.1 Urinalysis
  • 7.2.2 Complete blood count
  • 7.2.3 Electrolyte analysis
  • 7.2.4 Other laboratory tests
• 7.3 Imaging
  • 7.3.1 Ultrasound
  • 7.3.2 Intravenous pyelography
  • 7.3.3 KUB X-Rays
  • 7.3.4 CT-scan
  • 7.3.5 Other imaging types

Chapter 8 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Shock wave lithotripsy
• 8.3 Laparoscopy
• 8.4 Bladder catheterization
• 8.5 Steroid therapy
• 8.6 Other treatments

Chapter 9 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Adult
• 9.3 Pediatric

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amgen Inc.
• 11.3 The Anthem Group
• 11.4 F. Hoffmann-La Roche Ltd.
• 11.5 Nephrogenex Inc.
• 11.6 Novartis AG
• 11.7 Pfizer Inc.
• 11.8 Phraxis Inc.
• 11.9 Renal Associates P.A.
• 11.10 Sanofi